Aviva PLC raised its holdings in shares of Alkermes PLC (NASDAQ:ALKS) by 5.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,159 shares of the company’s stock after buying an additional 4,525 shares during the period. Aviva PLC owned about 0.06% of Alkermes PLC worth $5,111,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in ALKS. Capstone Asset Management Co. increased its holdings in Alkermes PLC by 8.0% during the first quarter. Capstone Asset Management Co. now owns 6,585 shares of the company’s stock valued at $385,000 after buying an additional 490 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in shares of Alkermes PLC by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock worth $222,000 after purchasing an additional 224 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Alkermes PLC by 545.9% in the first quarter. Acadian Asset Management LLC now owns 33,438 shares of the company’s stock worth $1,956,000 after purchasing an additional 28,261 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Alkermes PLC by 23.6% in the first quarter. Russell Investments Group Ltd. now owns 9,835 shares of the company’s stock worth $575,000 after purchasing an additional 1,877 shares in the last quarter. Finally, Sumitomo Mitsui Asset Management Company LTD increased its stake in shares of Alkermes PLC by 24.4% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 12,256 shares of the company’s stock worth $716,000 after purchasing an additional 2,406 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.
Alkermes PLC (ALKS) opened at 52.02 on Friday. Alkermes PLC has a 52-week low of $41.93 and a 52-week high of $63.40. The company’s market cap is $7.99 billion. The firm’s 50-day moving average is $51.70 and its 200 day moving average is $56.60.
Alkermes PLC (NASDAQ:ALKS) last announced its earnings results on Thursday, July 27th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The company had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $216.54 million. During the same quarter in the previous year, the company posted ($0.01) EPS. The firm’s quarterly revenue was up 12.1% on a year-over-year basis. On average, equities research analysts predict that Alkermes PLC will post ($0.04) EPS for the current fiscal year.
In other Alkermes PLC news, Director Paul J. Mitchell sold 1,500 shares of Alkermes PLC stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $58.11, for a total transaction of $87,165.00. Following the sale, the director now owns 9,500 shares of the company’s stock, valued at approximately $552,045. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Kathryn L. Biberstein sold 13,566 shares of Alkermes PLC stock in a transaction on Monday, September 11th. The stock was sold at an average price of $51.29, for a total transaction of $695,800.14. Following the sale, the chief accounting officer now directly owns 70,455 shares in the company, valued at approximately $3,613,636.95. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,066 shares of company stock worth $941,485. 5.34% of the stock is currently owned by corporate insiders.
A number of analysts have recently issued reports on ALKS shares. Zacks Investment Research raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Credit Suisse Group reissued a “buy” rating and issued a $70.00 price objective on shares of Alkermes PLC in a research note on Wednesday, June 7th. Leerink Swann lowered shares of Alkermes PLC from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $68.00 to $61.00 in a research report on Tuesday, June 13th. Jefferies Group LLC set a $69.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, August 25th. Finally, ValuEngine upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. Alkermes PLC presently has a consensus rating of “Hold” and an average target price of $62.89.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.